Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Blood Test Identifies Heart Failure with Preserved Ejection Fraction

By LabMedica International staff writers
Posted on 12 Nov 2018
A test based on a protein biomarker found in the blood is the basis of a scoring system that distinguishes patients with clinical heart failure with preserved ejection fraction (HFpEF) from healthy individuals and patients with risk factors but no heart failure.

Heart failure with preserved ejection fraction is a growing epidemic worldwide with a high burden of morbidity and mortality. More...
Lack of understanding of the pathology and physiology of the syndrome has limited development of diagnostic tools to define and follow the disease progression.

Cardiac bridging integrator 1 (cBIN1) is a membrane-scaffolding protein in cardiomyocytes that organizes the dyad-containing microdomains at the transverse tubules that are responsible for the initiation and regulation of systolic and diastolic calcium transients. The level of cBIN1 is reduced in animal models of heart failure, as well as in human biopsy samples from patients with end-stage cardiomyopathy. Its blood availability makes it an attractive biomarker of cardiomyocyte remodeling.

Investigators at Cedars-Sinai Medical Center (Los Angeles, CA, USA) determined cBIN1 scores (CS) from ELISA measurement of plasma cBIN1 concentrations from 52 stable, ambulatory patients with HFpEF from age-matched and sex-matched healthy individuals and participants with heart failure risk factors but no HFpEF. The analysis examined the ability of the CS and N-terminal pro-B-type natriuretic peptide (NT-proBNP) results to differentiate among the patients.

Results revealed that the CS values were significantly higher in the patients with HFpEF than in the two control cohorts. For patients with HFpEF, the CS outperformed NT-proBNP when the comparator group was either healthy control participants or those with risk factors. Thus, the plasma CS, a marker of transverse tubule dysfunction, serves as a biomarker of cardiomyocyte remodeling that has the potential to aide in the diagnosis of HFpEF.

"By the time heart failure symptoms develop, the critical window for corrective therapy has typically closed," said senior author Dr. Robin Shaw, professor of medicine at Cedars-Sinai Medical Center. "Our discovery allows us to not only diagnose the disease sooner, but also to treat patients before that critical period of early intervention for lifesaving care has closed."

The study was published in the October 31, 2018, online edition of the journal JAMA Cardiology.

Related Links:
Cedars-Sinai Medical Center


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Urine Chemistry Control
Dropper Urine Chemistry Control
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.